Brief: Telomir Pharmaceuticals Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
08/10/2025 22:20
Oct 8 (Reuters) - Telomir Pharmaceuticals Inc TELO.O: TELOMIR PHARMACEUTICALS INC: TELOMIR-1 SELECTIVELY KILLS AGGRESSIVE TRIPLE-NEGATIVE BREAST CANCER CELLS TELOMIR PHARMACEUTICALS: TELOMIR-1 SHUTS DOWN CELLULAR ENERGY PATHWAYS, MITOCHONDRIAL FUNCTION IN AGGRESSIVE BREAST CANCER CELLS - SEC FILING TELOMIR PHARMACEUTICALS: TELOMIR-1 SIGNIFICANTLY REDUCES SURVIVAL OF AGGRESSIVE TRIPLE-NEGATIVE BREAST CANCER CELLS - SEC FILING TELOMIR PHARMACEUTICALS: PLANS TO EXPAND STUDIES TO PANCREATIC, LEUKEMIA MODELS, CONDUCT FURTHER ANIMAL STUDIES FOR IND SUBMISSION - SEC FILING Further company coverage: TELO.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Telomir Pharmaceuticals
See all newsBrief: Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
Brief: Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases
Brief: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’S “Kill-And-Clean” Defense Systems In An Aggressive Prostate Cancer Model
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation